CoChat

Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery

Open access

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

The adoptive transfer of engineered T cells for the treatment of cancer, autoimmunity, and infectious disease is a rapidly growing field that has shown great promise in recent clinical trials. Nuclease-driven genome editing provides a method in which to precisely target genetic changes to further enhance T cell function in vivo. We describe the development of a highly efficient method to genome edit both primary human CD8 and CD4 T cells by homology-directed repair at a pre-defined site of the genome. Two different homology donor templates were evaluated, representing both minor gene editing events (restriction site insertion) to mimic gene correction, or the more significant insertion of a larger gene cassette. By combining zinc finger nuclease mRNA delivery with AAV6 delivery of a homologous donor we could gene correct 41% of CCR5 or 55% of PPP1R12C (AAVS1) alleles in CD8(+) T cells and gene targeting of a GFP transgene cassette in >40% of CD8(+) and CD4(+) T cells at both the CCR5 and AAVS1 safe harbor locus, potentially providing a robust genome editing tool for T cell-based immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gkv1121

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. CD8+ T cells are efficiently transduced by AAV serotype 6. (A) Schematic of recombinant AAV vector genomes containing CMV promoter-driven eGFP expression cassette. Inverted terminal repeats (ITRs) are derived from AAV2. Different serotype specific Cap genes were used to generate the corresponding recombinant AAV vectors as described in Materials And Methods. (B) CD8+ T cells were transduced with increasing doses of GFP-expressing AAV vectors of the indicated serotypes, and GFP expression was determined at 5 days post-transduction by flow cytometry. The vector doses used were 1 × 104, 3 × 104, 1 × 105, 3 × 105, 1 × 106 vector genomes (vg)/cell. Combined results of 3 independent experiments using different CD8+ T cell donors were shown as mean ± SD. (C) Flow cytometric plots from a representative experiment at 1 × 106 vg/cell are shown.
Figure 1. CD8+ T cells are efficiently transduced by AAV serotype 6. (A) Schematic of recombinant AAV vector genomes containing CMV promoter-driven eGFP expression cassette. Inverted terminal repeats (ITRs) are derived from AAV2. Different serotype specific Cap genes were used to generate the corresponding recombinant AAV vectors as described in Materials And Methods. (B) CD8+ T cells were transduced with increasing doses of GFP-expressing AAV vectors of the indicated serotypes, and GFP expression was determined at 5 days post-transduction by flow cytometry. The vector doses used were 1 × 104, 3 × 104, 1 × 105, 3 × 105, 1 × 106 vector genomes (vg)/cell. Combined results of 3 independent experiments using different CD8+ T cell donors were shown as mean ± SD. (C) Flow cytometric plots from a representative experiment at 1 × 106 vg/cell are shown.CC BY · PubMed Central
Figure 2. Combination of ZFN mRNA and AAV6 vectors promotes high levels of gene correction-like events at the CCR5 locus in CD8+ T cells. (A) Schematic showing use of AAV vector as a template for homology directed repair (HDR) of a double-strand break (DSB), as induced by target-specific nucleases, to introduce a corrected gene sequence or transgene into a predetermined genomic target site. (B) Schematic of AAV vector genomes containing CCR5-RFLP homology donors. L (left) and R (right) refer to CCR5 genomic sequences, comprising 509 and 1349 bp respectively. (C) CD8+ T cells were transduced with AAV6 vectors carrying the CCR5-RFLP donor at indicated doses for 16 hours, then electroporated with CCR5 ZFN mRNA (60μg/ml). Cells were analyzed 7 days post-electroporation by deep sequencing to measure the efficiency of genome modification (% indels and RFLP). Combined results of three experiments using three different CD8+ T cell donors are shown. Mean ± SD. *P < 0.05, two-tailed t-test to compare %RFLP between conditions with different doses of AAV6 donor in the presence of ZFN mRNA treatment. (D) Dose-dependent insertion of XhoI site at CCR5, confirmed by RFLP analysis. Adjusted%RFLP HDR are shown below the lanes with visible RFLP bands based on deep sequencing results of the undigested top band due to incomplete digestion. The %RFLP before adjustment are shown in parentheses. One representative experiment is shown.
Figure 2. Combination of ZFN mRNA and AAV6 vectors promotes high levels of gene correction-like events at the CCR5 locus in CD8+ T cells. (A) Schematic showing use of AAV vector as a template for homology directed repair (HDR) of a double-strand break (DSB), as induced by target-specific nucleases, to introduce a corrected gene sequence or transgene into a predetermined genomic target site. (B) Schematic of AAV vector genomes containing CCR5-RFLP homology donors. L (left) and R (right) refer to CCR5 genomic sequences, comprising 509 and 1349 bp respectively. (C) CD8+ T cells were transduced with AAV6 vectors carrying the CCR5-RFLP donor at indicated doses for 16 hours, then electroporated with CCR5 ZFN mRNA (60μg/ml). Cells were analyzed 7 days post-electroporation by deep sequencing to measure the efficiency of genome modification (% indels and RFLP). Combined results of three experiments using three different CD8+ T cell donors are shown. Mean ± SD. *P < 0.05, two-tailed t-test to compare %RFLP between conditions with different doses of AAV6 donor in the presence of ZFN mRNA treatment. (D) Dose-dependent insertion of XhoI site at CCR5, confirmed by RFLP analysis. Adjusted%RFLP HDR are shown below the lanes with visible RFLP bands based on deep sequencing results of the undigested top band due to incomplete digestion. The %RFLP before adjustment are shown in parentheses. One representative experiment is shown.CC BY · PubMed Central
Figure 3. Combination of ZFN mRNA and AAV6 vectors promotes high levels of transgene addition at the CCR5 locus in CD8+ T cells. (A) Schematic of AAV vector genomes containing CCR5-GFP homology donors. L (left) and R (right) refer to CCR5 genomic sequences, comprising 476 and 1428 bp, respectively. (B) CD8+ T cells were treated as described in Figure 2C, but using CCR5-GFP donor vectors, with and without CCR5 ZFN mRNA electroporation. Cells were collected at 14 days post-transduction and analyzed by flow cytometry for %GFP+, and by deep sequencing to measure% indels. Results were combined from three experiments using three different CD8+ T cell donors. Mean ± SD. *P < 0.05, two-tailed t-test to compare%GFP+ between conditions with different doses of AAV6 donor in the presence of ZFN mRNA treatment. (C) Flow cytometry plots from one representative experiment were shown using 1 × 106 vg/cell CCR5-GFP donor, at 14 days post-electroporation. (D) Confirmation of targeted integration of GFP expression cassette at the CCR5 locus by semi-quantitative PCR. The %GFP HDR was estimated by comparison to standards.
Figure 3. Combination of ZFN mRNA and AAV6 vectors promotes high levels of transgene addition at the CCR5 locus in CD8+ T cells. (A) Schematic of AAV vector genomes containing CCR5-GFP homology donors. L (left) and R (right) refer to CCR5 genomic sequences, comprising 476 and 1428 bp, respectively. (B) CD8+ T cells were treated as described in Figure 2C, but using CCR5-GFP donor vectors, with and without CCR5 ZFN mRNA electroporation. Cells were collected at 14 days post-transduction and analyzed by flow cytometry for %GFP+, and by deep sequencing to measure% indels. Results were combined from three experiments using three different CD8+ T cell donors. Mean ± SD. *P < 0.05, two-tailed t-test to compare%GFP+ between conditions with different doses of AAV6 donor in the presence of ZFN mRNA treatment. (C) Flow cytometry plots from one representative experiment were shown using 1 × 106 vg/cell CCR5-GFP donor, at 14 days post-electroporation. (D) Confirmation of targeted integration of GFP expression cassette at the CCR5 locus by semi-quantitative PCR. The %GFP HDR was estimated by comparison to standards.CC BY · PubMed Central
Figure 4. AAV6 vectors and ZFN mRNA promote high levels of gene correction-like events at the AAVS1 locus in CD8+ T cells. (A) Schematics of AAV6 vectors used to deliver AAVS1 homology donors. L (left) and R (right) refer to AAVS1 genomic sequences, comprising 789 and 837 bp respectively (11). (B) CD8+ T cells were transduced with AAV6 vectors carrying the AAVS1-RFLP donor at indicated doses (vg/cell) for 16 h and/or electroporated with AAVS1 ZFN mRNA. Cells were analyzed 7 days post-electroporation by Illumina deep sequencing to measure the efficiency of genome modification (% indels and RFLP). Results are combined from three experiments using three different CD8+ T cell donors. Mean ± SD. *P < 0.05, two-tailed t-test to compare%RFLP between conditions with different doses of AAV6 donor in the presence of ZFN mRNA treatment. (C) Confirmation of insertion of HindIII site at the AAVS1 locus by RFLP assay. Adjusted%RFLP HDR are shown below the lanes with visible RFLP bands based on deep sequencing results of the undigested top band due to incomplete digestion. The %RFLP before adjustment are shown in parentheses. One representative experiment is shown.
Figure 4. AAV6 vectors and ZFN mRNA promote high levels of gene correction-like events at the AAVS1 locus in CD8+ T cells. (A) Schematics of AAV6 vectors used to deliver AAVS1 homology donors. L (left) and R (right) refer to AAVS1 genomic sequences, comprising 789 and 837 bp respectively (11). (B) CD8+ T cells were transduced with AAV6 vectors carrying the AAVS1-RFLP donor at indicated doses (vg/cell) for 16 h and/or electroporated with AAVS1 ZFN mRNA. Cells were analyzed 7 days post-electroporation by Illumina deep sequencing to measure the efficiency of genome modification (% indels and RFLP). Results are combined from three experiments using three different CD8+ T cell donors. Mean ± SD. *P < 0.05, two-tailed t-test to compare%RFLP between conditions with different doses of AAV6 donor in the presence of ZFN mRNA treatment. (C) Confirmation of insertion of HindIII site at the AAVS1 locus by RFLP assay. Adjusted%RFLP HDR are shown below the lanes with visible RFLP bands based on deep sequencing results of the undigested top band due to incomplete digestion. The %RFLP before adjustment are shown in parentheses. One representative experiment is shown.CC BY · PubMed Central
Figure 5. AAV6 vectors and ZFN mRNA promote high levels of transgene addition at the AAVS1 locus in CD8+ T cells. (A) Schematics of AAV6 vectors used to deliver AAVS1-GFP homology donors. L (left) and R (right) refer to AAVS1 genomic sequences, comprising 789 and 570 bp, respectively. (B) CD8+ T cells were treated as described in Figure 4B, but using AAVS1-GFP donor. Cells were collected 14 days post-transduction and analyzed by flow cytometry for %GFP+, and by deep sequencing to measure% indels. Results were combined from three experiments using three different CD8+ T cell donors. Mean ± SD. *P < 0.05, two-tailed t-test to compare %GFP+ between conditions with different doses of AAV6 donor in the presence of ZFN mRNA treatment. (C) Flow cytometry plots from a representative experiment using 1 × 106 vg/cell AAVS1-GFP donor at 14 days post-electroporation.
Figure 5. AAV6 vectors and ZFN mRNA promote high levels of transgene addition at the AAVS1 locus in CD8+ T cells. (A) Schematics of AAV6 vectors used to deliver AAVS1-GFP homology donors. L (left) and R (right) refer to AAVS1 genomic sequences, comprising 789 and 570 bp, respectively. (B) CD8+ T cells were treated as described in Figure 4B, but using AAVS1-GFP donor. Cells were collected 14 days post-transduction and analyzed by flow cytometry for %GFP+, and by deep sequencing to measure% indels. Results were combined from three experiments using three different CD8+ T cell donors. Mean ± SD. *P < 0.05, two-tailed t-test to compare %GFP+ between conditions with different doses of AAV6 donor in the presence of ZFN mRNA treatment. (C) Flow cytometry plots from a representative experiment using 1 × 106 vg/cell AAVS1-GFP donor at 14 days post-electroporation.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 130

Metadata

Authors
Wang, J., DeClercq, J. J., Hayward, S. B., Li, P. W.-L., Shivak, D. A., Gregory, P. D., Lee, G., & Holmes, M. C.
Affiliations
Sangamo BioSciences (United States) (US)
Corresponding author
Wang, Jianbin
Venue
Nucleic Acids Research
Published
2015-11-02
Volume
44
Issue
3
Pages
e30-e30
ISSN
  • 0305-1048 (ISSN-L)
  • 1362-4962
OpenAlex
W1909557371
Cited by
128
References
54
Citations by year
2026: 11 · 2025: 2 · 2024: 7 · 2023: 14 · 2022: 13 · 2021: 14 · 2020: 11 · 2019: 18 · 2018: 16 · 2017: 13 · 2016: 9
FWCI
5.50
Type
journal article
Language
en
Open access
Locations
  • Nucleic Acids Research (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
genome editing, human T cells, zinc finger nucleases, AAV6 vector, homology-directed repair, CCR5, AAVS1 safe harbor, CD8+ T cells, CD4+ T cells, gene correction, adoptive T cell therapy, T cell engineering
MeSH terms
Dependovirus, Endonucleases, Genetic Vectors, Humans, RNA, Messenger, Transfection, CD4-Positive T-Lymphocytes, Genome, Human, Zinc Fingers, CD8-Positive T-Lymphocytes

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. https://app.cochat.ai/papers/10.1093/nar/gkv1121
The paper
Wang, J., DeClercq, J. J., Hayward, S. B., Li, P. W.-L., Shivak, D. A., Gregory, P. D., Lee, G., & Holmes, M. C. (2016). Highly efficient homology-driven genome editing in human T cells by combining zinc-finger nuclease mRNA and AAV6 donor delivery. Nucleic Acids Research. https://doi.org/10.1093/nar/gkv1121

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.